GlassScriptPhysician profile
Maged Habib
NPI 1508867540
$4,729.99
in general payments reported to CMS, 2019-2025
25 companies · $951 in 2025
The $951 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $218 · 2021: $466 · 2022: $352 · 2023: $538 · 2024: $1,002 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.89 | 2022-2025 | |
| Alcon Vision LLC | $743.99 | 2020-2025 | Clareon, Centurion, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $469.87 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $445.02 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $381.39 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $353.53 | 2019-2024 | Tecnis Iol |
| Sight Sciences, INC. | $228.16 | 2019-2024 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $187.08 | 2019-2023 | |
| Dompe US, INC. | $169.17 | 2021-2025 | Oxervate |
| Shire North American Group INC | $133.07 | 2019 | |
| Omeros Corporation | $125.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $118.74 | 2024 | Eylea Hd |
| Ivantis, INC | $99.20 | 2020 | |
| Mallinckrodt Hospital Products INC. | $98.48 | 2024 | Acthar |
| Harrow Eye, LLC | $94.03 | 2025 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $55.72 | 2022-2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Kala Pharmaceuticals, INC. | $37.62 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $36.33 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $33.18 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $30.21 | 2024 | |
| Rayner Intraocular Lenses Limited | $26.20 | 2025 | Omidria |
| Thea Pharma INC. | $25.00 | 2025 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $19.21 | 2022 | |
| Halozyme INC | $17.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Habib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.